Screener
Celldex Therapeutics CLDX EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Celldex Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Celldex Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091984
FAQ
- What is Celldex Therapeutics's EBITDA margin?
- Celldex Therapeutics (CLDX) reported EBITDA margin of -204,070.9% in Q2 2026.
- How has Celldex Therapeutics's EBITDA margin changed year-over-year?
- Celldex Therapeutics's EBITDA margin decreased by 5007.0% year-over-year, from -3,995.9% to -204,070.9%.
- What is the long-term trend for Celldex Therapeutics's EBITDA margin?
- Over 5 years (2020 to 2025), Celldex Therapeutics's EBITDA margin has grown at a 87.1% compound annual growth rate (CAGR), from -801.1% to -18,369.1%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.
Ask your AI about Celldex Therapeutics's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude